A Potential Drug Target or Biomarker: Unlocking the Potential of CDC42SE2
A Potential Drug Target or Biomarker: Unlocking the Potential of CDC42SE2
CDC42SE2, also known as CDC42 small effector 2, is a protein that plays a crucial role in cell signaling and cytoskeletal organization. It is a member of the CDC42 family, which is known for its role in regulating cell division, cytoskeletal organization, and other cellular processes. In recent years, researchers have identified CDC42SE2 as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.
CDC42SE2: Structure and Function
CDC42SE2 is a 21-kDa protein that consists of 215 amino acid residues. It has a unique structure, with a catalytic core and a N-terminal region that is involved in its interactions with other proteins. The catalytic core of CDC42SE2 consists of a parallel beta-sheet, which is flanked by alpha-helices that contain the protein's active site. The N-terminal region contains a unique glycine-rich region that is involved in the protein's stability and interaction with other proteins.
CDC42SE2 is involved in a wide range of cellular processes, including cell signaling, cytoskeletal organization, and cell division. It plays a critical role in the regulation of mitosis, meiosis, and cell division, and is involved in the formation of the cytoskeleton, as well as the organization of organelles such as the endoplasmic reticulum and the mitochondria.
CDC42SE2 has also been shown to play a role in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. For example, studies have shown that CDC42SE2 is overexpressed or hyperactive in various cancer types, including breast, ovarian, and colorectal cancers. This suggests that targeting CDC42SE2 may be an effective way to treat these diseases.
Drug Targeting Strategies
Drug targeting strategies for CDC42SE2 have a variety of potential approaches, including inhibition of its catalytic activity, modulation of its stability, and disruption of its interactions with other proteins. One approach is to inhibit the activity of CDC42SE2 using small molecules or antibodies that target its catalytic active site. This would prevent the protein from catalyzing various cellular processes and disrupt its normal function.
Another approach is to modulate CDC42SE2's stability by altering its N-terminal region. This could involve introducing mutations or altering the structure of the N-terminal region to reduce its stability or enhance its stability. This approach could be useful for diseases where disruptions in CDC42SE2's stability are believed to contribute to its pathogenesis.
Another potential approach to drug targeting CDC42SE2 is to disrupt its interactions with other proteins. This could involve introducing mutations or altering the structure of the protein to alter its interactions with other proteins. This approach could be useful for diseases where disruptions in these interactions are believed to contribute to its pathogenesis.
Biomarker Potential
CDC42SE2 has the potential to serve as a biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its overexpression or hyperactivity in these diseases suggests that targeting CDC42SE2 may be an effective way to diagnose and treat these diseases.
For example, studies have shown that CDC42SE2 is overexpressed or hyperactive in various cancer types, including breast, ovarian, and colorectal cancers. This suggests that targeting CDC42SE2
Protein Name: CDC42 Small Effector 2
Functions: Probably involved in the organization of the actin cytoskeleton by acting downstream of CDC42, inducing actin filament assembly. Alters CDC42-induced cell shape changes. In activated T-cells, may play a role in CDC42-mediated F-actin accumulation at the immunological synapse. May play a role in early contractile events in phagocytosis in macrophages
The "CDC42SE2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC42SE2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3
